



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: KEMBLE, George et al.

Art Unit: 1648

Serial No.: 09/724,935

Examiner: Stacy B. Chen

Filed: November 28, 2000

Atty. Docket: CM101US

For: ATTENUATION OF  
CYTOMEGALOVIRUS VIRULENCE

**Information Disclosure Statement Under 37 CFR 1.97**

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.


This information disclosure statement is submitted prior to the mailing of a first Office Action, therefore, no fee is believed due. However, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 500479.

December 8, 2004

Respectfully submitted,

By:   
Patrick Scott Alban, Reg. No. 48,714

**MEDIMMUNE, INC.**  
One MedImmune Way  
Gaithersburg, Maryland 20878  
(301) 398-4176 (T) (301) 398-9280 (F)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/724,935
		Filing Date	November 28, 2000
		First Named Inventor	KEMBLE, George
		Art Unit	1648
		Examiner Name	Stacey B. Chen
Sheet 1	of 1	Attorney Docket Number	CM101US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A.	PLOTKIN, April, 1999, "Vaccination Against Cytomegalovirus, The Changeling Demon," <i>Pediatr Infect Dis J.</i> , 18:313-326	
	B.	KEMBLE et al., 1996, "A New Generation of Live, Attenuated Cytomegalovirus (CMV) Vaccine Strains," <i>Interscience Conf. Antimicrob. Agents and Chem</i> , H88	
	C.	KEMBLE et al., 1997, "Derivation of Novel, Recombinant, Live, Attenuated CMV Vaccine Strains," 6th Int. Cytomegalovirus Workshop, A-25(49)	
	D.	BEISEL, 2000, "Cytomegalovirus Vaccine Development," <i>Jordan Reprt</i> , 105-110	
	E.	KEMBLE et al., July, 1999, "Development of Live, Attenuated Human Cytomegalovirus Vaccine Candidates," 24th Inter. Herpesvirus Workshop; 13.007	
	F.	SPATE et al., 1997, "Progress in Developing a CMV Vaccine, Virology Seminar; Max-von-Pettenkofer Institute und Genz, Munchen, Germany; 1-13	
	G.	SPATE et al., "Controlling CMV through Vaccination," March 20-22, 1998, Science Symposium; Tucson AZ	
	H.	SPATE et al., 1998, "Progress in Developing a CMV Vaccine," Virology Seminar; University of California - Irvine	
	I.	KEMBLE et al., April, 1999, "Towne/Toledo Vaccine Development," 7th Intl. Cytomegalovirus Workshop, Brighton, U.K.,	
	J.	KEMBLE et al., 1996, "Genetic Determinanats of CMV Virulence," 21st Herpesvirus Workshop; 315	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.